Target Identification/ Validation News for June 2016

MRC Technology and AstraZeneca call for epigenetic targets in respiratory disease MRC Technology and AstraZeneca call for epigenetic targets in respiratory disease

MRC Technology (MRCT), a medical research charity, and AstraZeneca, a global biopharmaceutical company, are launching an initiative to find new epigenetic drug targets in respiratory disease. MRCT and AstraZeneca are now seeking academics with relevant epigenetics targets to collaborate with them to develop novel treatments for respiratory diseases, which affect millions of people every year.
15 June, 2016